Upgrades Hold Buy X

PCRX Pacira BioSciences

Truist

$30

Upgrades Sell Hold X

PCRX Pacira BioSciences

Truist

$8 $25

Downgrades Buy Sell X

PCRX Pacira BioSciences

Truist

$30 $8

Downgrades Overweight Underweight X

PCRX Pacira BioSciences

JP Morgan

$45 $10

Downgrades Overweight Neutral X

PCRX Pacira BioSciences

Piper Sandler

$42 $11

Downgrades Outperform Mkt Perform X

PCRX Pacira BioSciences

Raymond James

Downgrades Outperform Sec Perform X

PCRX Pacira BioSciences

RBC Capital Mkts

$37 $14

Downgrades Overweight Eq Weight X

PCRX Pacira BioSciences

Barclays

$38 $25

Resumed Overweight X

PCRX Pacira BioSciences

JP Morgan

$80 $45

Upgrades Mkt Perform Outperform X

PCRX Pacira BioSciences

TD Cowen

$50

Resumed Outperform X

PCRX Pacira BioSciences

Wedbush

$88 $60

Resumed Buy X

PCRX Pacira BioSciences

Jefferies

$66

Resumed Overweight X

PCRX Pacira BioSciences

JP Morgan

$75 $83

Upgrades Neutral Overweight X

PCRX Pacira BioSciences

JP Morgan

$75

Resumed Neutral X

PCRX Pacira BioSciences

JP Morgan

$70

Initiated Buy X

PCRX Pacira Pharma

Berenberg

$93

Resumed Outperform X

PCRX Pacira Pharma

RBC Capital Mkts

$86

Downgrades Outperform Mkt Perform X

PCRX Pacira Pharma

Northland Capital

$72 $75

Downgrades Outperform Mkt Perform X

PCRX Pacira Pharma

SVB Leerink

$75

Initiated Overweight X

PCRX Pacira Pharma

Barclays

$52

Upgrades Underperform Neutral X

PCRX Pacira Pharma

Mizuho

$29 $38

Downgrades Neutral Underperform X

PCRX Pacira Pharma

Mizuho

Downgrades Buy Neutral X

PCRX Pacira Pharma

BofA/Merrill

Reiterated Buy X

PCRX Pacira Pharma

H.C. Wainwright

$45 $48

Reiterated Neutral X

PCRX Pacira Pharma

Mizuho

$44 $31

Downgrades Buy Hold X

PCRX Pacira Pharma

Needham

PCRX  Pacira Pharmaceuticals, Inc.

Pacira Pharmaceuticals, Inc. is a holding company. The Company is a pharmaceutical company focused on the development, manufacture and commercialization of pharmaceutical products, based on its DepoFoam extended release drug delivery technology, for use primarily in hospitals and ambulatory surgery centers. Its lead product candidate is EXPAREL (bupivacaine liposome injectable suspension), which consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam and is indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. In addition to EXPAREL, DepoFoam is also the basis for its other Food and Drug Administration-approved commercial product, DepoCyt(e), which it manufactures for its commercial partners, as well as its product candidates. The Company's other product candidates include DepoMeloxicam (DepoMLX) and DepoTranexamic Acid (DepoTXA). DepoCyt(e) is indicated for the intrathecal treatment of lymphomatous meningitis.